Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/31067
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorMendoza, Nicolás-
dc.contributor.authorAbad, Pedro-
dc.contributor.authorBARO, FRANCESC-
dc.contributor.authorCancelo, Maria Jesús-
dc.contributor.authorLlaneza, Plácido-
dc.contributor.authorManubens, Montserrat-
dc.contributor.authorQuereda, Francisco-
dc.contributor.authorSánchez-Borrego, Rafael-
dc.contributor.otherDepartamentos de la UMH::Salud Pública, Historia de la Ciencia y Ginecologíaes_ES
dc.date.accessioned2024-02-05T12:40:43Z-
dc.date.available2024-02-05T12:40:43Z-
dc.date.created2012-10-25-
dc.identifier.citationMenopause. 2013 Jul;20(7):754-60es_ES
dc.identifier.issn1530-0374-
dc.identifier.issn1072-3714-
dc.identifier.urihttps://hdl.handle.net/11000/31067-
dc.description.abstractTibolone is a drug with complex tissue-specific action that exhibits a combination of estrogenic, progestogenic, and slight androgenic activity. Its variable profile explains its clinical effects, depending on the target tissue where it is metabolized, its metabolites’ affinity for and potency in hormone receptors, and probable enzymatic activity modulation. In recent reviews and clinical trials, the effectiveness of tibolone in alleviating different hot flush menopause symptoms, mainly in mood and sexuality disorders, has been noted. In Spain, tibolone is the most prescribed hormonal treatment, and one of the most common complaints among postmenopausal women is change in sexual drive. For such reason, a panel of experts from the Spanish Menopause Society met to develop usage recommendations based on the best evidence available.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent7es_ES
dc.language.isoenges_ES
dc.publisherLippincott, Williams & Wilkinses_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectTibolonees_ES
dc.subjectPostmenopausales_ES
dc.subjectHormone therapyes_ES
dc.titleSpanish Menopause Society position statement: use of tibolone in postmenopausal womenes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1097/GME.0b013e31827b18c5es_ES
Aparece en las colecciones:
Artículos Salud Pública, Historia de la Ciencia y Ginecología


no-thumbnailVer/Abrir:

 Spanish Menopause Society position statement use of tibolone.pdf



226,75 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.